Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.8%. By the end of trading, Eli Lilly and Company rose $1.12 (2.4%) to $47.03 on average volume. Throughout the day, 8.4 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 9.1 million shares. The stock ranged in a price between $46.15-$47.07 after having opened the day at $46.30 as compared to the previous trading day's close of $45.91. Other companies within the Drugs industry that increased today were: ACADIA Pharmaceuticals ( ACAD), up 18.3%, AVANIR Pharmaceuticals ( AVNR), up 16.6%, BioTime ( BTX), up 15.1%, and Ligand Pharmaceuticals ( LGND), up 14.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $53.33 billion and is part of the health care sector. The company has a P/E ratio of 12.5, below the S&P 500 P/E ratio of 17.7. Shares are up 10.6% year to date as of the close of trading on Friday. Currently there are five analysts that rate Eli Lilly and Company a buy, three analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%